NewDays

High-Level Overview

NewDays is a Seattle-based AI-powered healthtech startup that provides personalized cognitive treatment for individuals with dementia or mild cognitive impairment, primarily those over 65.[1][2][3] It combines telehealth appointments with licensed cognitive clinicians and AI-guided brain exercises via its companion "Sunny," addressing the needs of an estimated one in three seniors facing serious cognitive issues by delivering scalable, insurance-accepted therapy that delays decline and reduces isolation.[1][2][3] The platform accepts insurance for clinician visits while charging $99/month for AI homework, serving patients in states like California, Washington, Florida, and Texas, with 100% of customers reporting feeling better and a 4.5/5 satisfaction rating.[1][2]

Recently securing $7M in seed funding from General Catalyst and Madrona (plus an additional $4.5M), NewDays is expanding its team, geographic reach, and AI platform to scale evidence-based interventions backed by Harvard-led trials like I-CONECT, which it exclusively licenses.[1][3][4]

Origin Story

NewDays emerged from clinical research breakthroughs, notably the Internet-Based Conversational Engagement Clinical Trial (I-CONECT) led by Dr. Hiroko Dodge at Harvard University, which demonstrated that structured clinician conversations delay cognitive decline in adults over 75.[1][3] The company holds an exclusive license to this protocol, transitioning time-intensive therapies—previously limited by scarce specialists—into an AI-human hybrid model for broader access.[1][5]

Founded in Seattle, it launched operations in Washington, California, Florida, and Texas, led by CEO Babak Parviz, who emphasizes applying "gold standard" neuropsychological methods via AI like Sunny to keep minds active through conversations and puzzles, akin to physical therapy for cognition.[2] Backed by a decade-long relationship with investor Madrona, NewDays gained early traction with its program rollout and recent funding rounds totaling over $11.5M from top VCs like General Catalyst and Madrona.[1][4][5]

Core Differentiators

• AI-Human Hybrid Model: Blends regular telehealth with licensed clinicians and Sunny's 24/7 personalized exercises (e.g., memory puzzles, reflective questions), scaling therapies that were previously bottlenecked by professional availability while maintaining clinical oversight.[1][2][3][5]
• Clinically Proven Foundation: Sunny is trained exclusively on I-CONECT trial data from Harvard, proven to delay decline and combat loneliness; no other platform holds this license.[1][3]
• Accessibility and Affordability: Insurance-covered clinician visits, $99/month AI companion, no waitlists, and data privacy; available in multiple states with free consultations.[1][2][3]
• User Outcomes and Experience: 100% customer satisfaction improvement, 4.5/5 rating; feels like "companionship" with engaging, non-clinical interactions.[1][2][3]

Role in the Broader Tech Landscape

NewDays rides the wave of generative AI in digital health, targeting the exploding dementia crisis—over 7 million Americans affected, projected to grow with aging populations—by democratizing cognitive therapies amid clinician shortages.[1][2] Timing aligns with AI advancements enabling conversational agents like Sunny, validated by rigorous trials, filling gaps in traditional care that's often inaccessible or under-scaled.[1][5]

Market forces favor it: rising senior demographics, payer interest in cost-effective interventions (e.g., insurance acceptance), and VC enthusiasm for AI-health intersections, as seen in funding from General Catalyst and Madrona.[1][4] It influences the ecosystem by pioneering AI for non-drug cognitive care, potentially setting standards for hybrid models in aging tech and reducing healthcare burdens through preventive, at-home scaling.[2][5]

Quick Take & Future Outlook

NewDays is poised to expand nationwide, leveraging fresh funding for team growth, tech enhancements, and new states like Texas, while iterating Sunny on real-user data to refine outcomes.[1][4] Trends like multimodal AI, payer adoption of virtual therapies, and longevity tech will propel it, especially as dementia cases surge and regulators greenlight AI clinical tools.

Its influence could evolve from niche player to category leader, inspiring AI companions across chronic care and amplifying investor bets on human-AI health synergies—exemplifying how tech finally tackles cognitive aging at scale, much like its mission promises: fighting decline to help people "live better and longer as themselves."[3]